1459 related articles for article (PubMed ID: 12538684)
1. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
2. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
[TBL] [Abstract][Full Text] [Related]
3. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
4. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
[TBL] [Abstract][Full Text] [Related]
6. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.
Selenko-Gebauer N; Majdic O; Szekeres A; Höfler G; Guthann E; Korthäuer U; Zlabinger G; Steinberger P; Pickl WF; Stockinger H; Knapp W; Stöckl J
J Immunol; 2003 Apr; 170(7):3637-44. PubMed ID: 12646628
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation.
Kuipers H; Muskens F; Willart M; Hijdra D; van Assema FB; Coyle AJ; Hoogsteden HC; Lambrecht BN
Eur J Immunol; 2006 Sep; 36(9):2472-82. PubMed ID: 16917960
[TBL] [Abstract][Full Text] [Related]
9. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Latchman Y; Wood CR; Chernova T; Chaudhary D; Borde M; Chernova I; Iwai Y; Long AJ; Brown JA; Nunes R; Greenfield EA; Bourque K; Boussiotis VA; Carter LL; Carreno BM; Malenkovich N; Nishimura H; Okazaki T; Honjo T; Sharpe AH; Freeman GJ
Nat Immunol; 2001 Mar; 2(3):261-8. PubMed ID: 11224527
[TBL] [Abstract][Full Text] [Related]
10. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
[TBL] [Abstract][Full Text] [Related]
11. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
[TBL] [Abstract][Full Text] [Related]
12. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
Zhu B; Guleria I; Khosroshahi A; Chitnis T; Imitola J; Azuma M; Yagita H; Sayegh MH; Khoury SJ
J Immunol; 2006 Mar; 176(6):3480-9. PubMed ID: 16517716
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.
Chen C; Qu QX; Huang JA; Zhu YB; Ge Y; Wang Q; Zhang XG
Immunobiology; 2007; 212(3):159-65. PubMed ID: 17412283
[TBL] [Abstract][Full Text] [Related]
14. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
Kinter AL; Godbout EJ; McNally JP; Sereti I; Roby GA; O'Shea MA; Fauci AS
J Immunol; 2008 Nov; 181(10):6738-46. PubMed ID: 18981091
[TBL] [Abstract][Full Text] [Related]
15. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activity.
Peña-Cruz V; McDonough SM; Diaz-Griffero F; Crum CP; Carrasco RD; Freeman GJ
J Invest Dermatol; 2010 Sep; 130(9):2222-30. PubMed ID: 20445553
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
17. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
18. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
[TBL] [Abstract][Full Text] [Related]
19. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 targeting can promote allograft survival.
Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
